KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Cash from Financing Activities data on record, last reported at $591.2 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1440.05% year-over-year to $591.2 million; the TTM value through Dec 2025 reached $675.8 million, up 41.37%, while the annual FY2025 figure was $675.8 million, 41.37% up from the prior year.
  • Cash from Financing Activities reached $591.2 million in Q4 2025 per IONS's latest filing, up from $81.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $591.2 million in Q4 2025 and bottomed at -$62.5 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $99.4 million, with a median of $2.0 million recorded in 2022.
  • The widest YoY moves for Cash from Financing Activities: up 11713.83% in 2023, down 1859.38% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$62.5 million in 2021, then grew by 18.36% to -$51.0 million in 2022, then soared by 179.82% to $40.7 million in 2023, then plummeted by 208.33% to -$44.1 million in 2024, then surged by 1440.05% to $591.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $591.2 million in Q4 2025, $81.2 million in Q3 2025, and $1.2 million in Q2 2025.